# Portola Pharmaceuticals clinical trials: 23 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with Portola Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Portola Pharmaceuticals: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/portola-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 16, 2019 | NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | Portola Pharmaceuticals | Phase 2/3 | Withdrawn | Peripheral T-Cell Lymphoma (PTCL NOS), Nodal Lymphomas of T Follicular Helper (TFH), Follicular T-cell Lymphoma (FTCL)... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04021082) |
| August 3, 2018 | NCT03613402 | BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes | Portola Pharmaceuticals | Observational | Withdrawn | Venous Thromboses | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03613402) |
| July 6, 2018 | NCT03578146 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory... | Portola Pharmaceuticals | Phase 2 | Completed | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03578146) |
| June 11, 2018 | NCT03551743 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory... | Portola Pharmaceuticals | Phase 2 | Completed | Healthy Volunteers | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03551743) |
| June 11, 2018 | NCT03551730 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory... | Portola Pharmaceuticals | Phase 2 | Completed | Healthy Volunteers | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03551730) |
| January 12, 2018 | NCT03397888 | The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist | Portola Pharmaceuticals | Phase 1 | Completed | Hepatic Impairment | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03397888) |
| November 6, 2017 | NCT03330457 | A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing | Portola Pharmaceuticals | Phase 2 | Terminated | Bleeding | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03330457) |
| October 16, 2017 | NCT03310021 | A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and... | Portola Pharmaceuticals | Phase 2 | Completed | Bleeding | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03310021) |
| July 14, 2017 | NCT03218241 | Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote | Portola Pharmaceuticals | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03218241) |
| March 20, 2017 | NCT03083704 | A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa | Portola Pharmaceuticals | Phase 1 | Completed | Bleeding | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03083704) |
| November 4, 2015 | NCT02596100 | A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations | Portola Pharmaceuticals | Phase 1 | Completed | Healthy | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02596100) |
| August 20, 2014 | NCT02220725 | A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban | Portola Pharmaceuticals | Phase 3 | Completed | Bleeding | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02220725) |
| August 4, 2014 | NCT02207725 | A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban | Portola Pharmaceuticals | Phase 3 | Completed | Bleeding | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02207725) |
| January 10, 2013 | NCT01765868 | A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers | Portola Pharmaceuticals | Phase 1 | Completed | Healthy Subjects | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01765868) |
| January 10, 2013 | NCT01765855 | An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects | Portola Pharmaceuticals | Phase 1 | Completed | Health Volunteers | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01765855) |
| January 1, 2013 | NCT01758432 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory... | Portola Pharmaceuticals | Phase 2 | Completed | Healthy Volunteers | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01758432) |
| April 23, 2012 | NCT01583218 | Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) | Portola Pharmaceuticals | Phase 3 | Completed | Venous Thromboembolism (VTE) | 7,513 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01583218) |
| October 27, 2010 | NCT01229254 | Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter | Portola Pharmaceuticals | Phase 2 | Completed | Atrial Fibrillation, Atrial Flutter | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01229254) |
| October 21, 2009 | NCT00999336 | A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe... | Portola Pharmaceuticals | Phase 1 | Completed | Renal Impairment | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00999336) |
| September 25, 2009 | NCT00984113 | Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment | Portola Pharmaceuticals | Phase 1 | Terminated | Renal Impairment | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00984113) |
| September 11, 2008 | NCT00751231 | A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI | Portola Pharmaceuticals | Phase 2 | Completed | Percutaneous Coronary Intervention | 652 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00751231) |
| August 28, 2008 | NCT00742859 | Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin | Portola Pharmaceuticals | Phase 2 | Completed | Atrial Fibrillation | 508 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00742859) |
| September 13, 2006 | NCT00375609 | Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) | Portola Pharmaceuticals | Phase 2 | Completed | Thromboembolism | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00375609) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 2 | 10 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Terminated | 2 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hemorrhage | 5 |
| Atrial Fibrillation | 2 |
| Renal Insufficiency | 2 |
| Lymphoma, T-Cell, Peripheral | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Leukemia, T-Cell | 1 |
| Atrial Flutter | 1 |
| Venous Thromboembolism | 1 |
| Venous Thrombosis | 1 |
| Thromboembolism | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Towing companies in the United States](https://specstream.ai/data/businesses/towing-companies/united-states)
- [Office supply stores in the United States](https://specstream.ai/data/businesses/office-supply-stores/united-states)
- [Flour mills in the United States](https://specstream.ai/data/businesses/flour-mills/united-states)
- [Bed and breakfasts in the United States](https://specstream.ai/data/businesses/bed-and-breakfasts/united-states)
- [Stock brokers in the United States](https://specstream.ai/data/businesses/stock-brokers/united-states)
